Targeting ACE2 in the Renin–Angiotensin–Aldosterone System: Post-COVID (Long-Term) Cardiovascular Sequelae
Journal of Experimental Pharmacology and Toxicology · 15.06.2026 · 4 (1) · 1
DOI: 10.64253/042026jept002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Pharmacology and Toxicology, online erschienen am 15.06.2026. Verfasst von Omotayo Alaba Eluwole und 1 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiovascular diseases (CVDs) and the coronavirus disease 2019 (COVID-19) pandemic represent major, interrelated global health challenges, largely mediated by dysregulation of the renin–angiotensin–aldosterone system (RAAS). Traditionally, therapeutic strategies have focused on inhibiting the classical ACE/angiotensin II (Ang II)/AT1 receptor axis, which drives vasoconstriction, inflammation, fibrosis, and cardiovascular remodeling. However, the discovery of angiotensin-converting enzyme 2 (ACE2) has revealed an alternative, counter-regulatory RAAS pathway with significant physiological and therapeutic relevance, particularly in the context of COVID-19. ACE2 catalyzes the conversion of Ang II to angiotensin-(1–7), thereby activating the Mas receptor axis, which exerts vasodilatory, anti-inflammatory, antifibrotic, and antioxidative effects. SARS-CoV-2-induced downregulation of ACE2 disrupts this protective pathway, contributing to cardiovascular injury and post-COVID-19 complications. This review examines classical and alternative RAAS signaling, elucidates the molecular basis of ACE2-mediated cardioprotection, and critically evaluates emerging therapeutic strategies, including natural products targeting the ACE2/angiotensin-(1–7)/Mas receptor axis in cardiovascular disease and post-COVID-19 complications.
Zitieren
APA
Eluwole, O. A., & Ogunlade, O. (2026). Targeting ACE2 in the Renin–Angiotensin–Aldosterone System: Post-COVID (Long-Term) Cardiovascular Sequelae. Journal of Experimental Pharmacology and Toxicology, 4(1), 1. https://doi.org/10.64253/042026jept002
Vancouver
Eluwole OA, Ogunlade O. Targeting ACE2 in the Renin–Angiotensin–Aldosterone System: Post-COVID (Long-Term) Cardiovascular Sequelae. Journal of Experimental Pharmacology and Toxicology. 2026;4(1):1. doi:10.64253/042026jept002
BibTeX
@article{Eluwole2026,
author = {Eluwole, Omotayo Alaba and Ogunlade, Oluwadare},
title = {Targeting ACE2 in the Renin–Angiotensin–Aldosterone System: Post-COVID (Long-Term) Cardiovascular Sequelae},
journal = {Journal of Experimental Pharmacology and Toxicology},
year = {2026},
volume = {4},
number = {1},
pages = {1},
doi = {10.64253/042026jept002}
}
EUVIMED